Physician
Samoilova, Elena
Samoilova, Elena was paid $975K by Medicaid between Jan 2018 and Dec 2024, across 66 billing codes. Its largest line is 80307, Drug test(s), presumptive, any number of drug classes; immunoassay — 20% of everything it billed.
33Billing provider infoSAMOILOVA, ELENA
LEXINGTON, KY 40536
LEXINGTON, KY 40536
33aNPI1215132550assigned 06/18/2007
33bProvider typeAnatomic Pathology & Clinical Pathology Physician
28Total paid$975K
24GClaims101,349
24DCodes billed66
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Anatomic Pathology & Clinical Pathology Physician providers in Kentucky
Rank by total paid#9 of 27
Median peer was paid$139K
This provider vs. median7.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 11,888 | $80K | |
| 2019 | 15,574 | $105K | |
| 2020 | 16,869 | $125K | |
| 2021 | 16,360 | $198K | |
| 2022 | 15,729 | $207K | |
| 2023 | 10,592 | $125K | |
| 2024incomplete | 14,337 | $134K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 20% | 2,280 | 1,858 | $191K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 11% | 3,164 | 2,693 | $106K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 9.9% | 2,697 | 2,505 | $96K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 9.3% | 2,751 | 2,516 | $91K |
| 80053 | Comprehensive metabolic panel | 7.4% | 13,942 | 11,499 | $72K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 6.7% | 3,006 | 2,848 | $66K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 6.2% | 16,440 | 12,974 | $60K |
| 88307 | 3.5% | 451 | 383 | $34K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 3.1% | 5,851 | 5,087 | $30K |
| 84703 | 2.0% | 5,411 | 4,794 | $19K | |
| 84484 | 1.7% | 3,894 | 3,201 | $17K | |
| 84443 | Thyroid stimulating hormone (TSH) | 1.6% | 1,952 | 1,760 | $16K |
54 more codes
| 83690 | 1.5% | 4,471 | $15K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.5% | 187 | $15K |
| 88342 | 1.5% | 876 | $15K | |
| 81001 | 1.4% | 9,665 | $13K | |
| 83735 | <1% | 2,895 | $10K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,176 | $9K |
| 83880 | <1% | 757 | $8K | |
| 87634 | <1% | 301 | $8K | |
| 82805 | <1% | 398 | $7K | |
| 87186 | <1% | 1,097 | $6K | |
| 84702 | <1% | 1,095 | $5K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 258 | $5K |
| 87040 | <1% | 382 | $5K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 198 | $4K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 196 | $4K |
| 88108 | <1% | 401 | $4K | |
| 83605 | <1% | 830 | $4K | |
| 85610 | <1% | 1,894 | $4K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,012 | $4K |
| 80061 | Lipid panel | <1% | 933 | $3K |
| 88141 | <1% | 304 | $3K | |
| 85378 | <1% | 838 | $3K | |
| 86901 | <1% | 1,007 | $2K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 284 | $2K |
| 85730 | <1% | 735 | $2K | |
| 86850 | <1% | 700 | $2K | |
| 86900 | <1% | 977 | $2K | |
| 82962 | <1% | 1,080 | $2K | |
| 88304 | <1% | 88 | $2K | |
| 85027 | <1% | 842 | $1K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 84 | $1K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 322 | $990.80 |
| 82728 | <1% | 227 | $952.68 | |
| 88341 | <1% | 13 | $867.50 | |
| 84466 | <1% | 179 | $781.18 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 30 | $719.40 |
| 83540 | <1% | 198 | $622.82 | |
| 86780 | <1% | 71 | $587.52 | |
| 86140 | <1% | 180 | $423.00 | |
| 82607 | <1% | 62 | $372.00 | |
| 84165 | <1% | 69 | $316.79 | |
| 80306 | <1% | 50 | $299.04 | |
| 85007 | <1% | 390 | $229.25 | |
| 87210 | <1% | 84 | $185.65 | |
| 86704 | <1% | 12 | $94.20 | |
| 85652 | <1% | 45 | $75.99 | |
| 80050 | General health panel | <1% | 394 | $74.55 |
| 85014 | <1% | 50 | $56.84 | |
| 85018 | <1% | 51 | $56.84 | |
| 82550 | <1% | 16 | $42.56 | |
| 87077 | <1% | 35 | $30.70 | |
| 84550 | <1% | 18 | $2.57 | |
| 84145 | 0% | 17 | $0.00 | |
| 80320 | 0% | 36 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.